RMD Stock Analysis — ResMed
Sector: Healthcare
AI Verdict
ResMed trades at 15.8x next year's earnings while analysts expect 25.6% EPS growth—cheap for the growth on offer if its cloud-connected ecosystem keeps competitors at bay.
Competitive Moat
ResMed dominates the sleep apnea device market with a vast installed base of CPAP machines and a proprietary cloud-connected platform that locks in patients and providers. Its data-driven ecosystem creates high switching costs for both patients and healthcare systems.
Summary
ResMed is notable for its cloud-connected CPAP devices and the sticky recurring revenue from patient monitoring.
Where It Stands
ResMed has a 1-year return of -19.78%, trades at 15.8x forward earnings versus the healthcare sector median of 22x, and its RSI of 59.0 is neutral.
Key Metrics
- RSI: 59 — Neutral
- Trailing P/E: 19.8x
- Forward P/E: 15.8x
- PEG Ratio: 0.62
- Earnings Growth: +0.3%
- Revenue Growth: +0.1%
- Market Cap: $29.9B
- Dividend Yield: 0.01%
- 1-Year Return: -19.78%
- 52-Week High: $293.81
- 52-Week Low: $180.26
Analyst Consensus
14 Buy · 9 Hold · 2 Sell (25 analysts)
Bull Case
With analysts forecasting 25.6% EPS growth and a forward P/E of just 15.8x, you're paying a below-average price for above-average growth if the moat holds.
Bear Case
If the forward P/E reverts to the sector median of 22x, the stock could see a re-rating, but if earnings disappoint, the 59.0 RSI leaves room for a further pullback.
Catalyst to Watch
Watch for upcoming clinical data or regulatory changes that could impact CPAP adoption rates or reimbursement.